Current measures of anticancer drug efficacy reflect bulk cell killing and are poorly suited to detect activity against cancer stem cells (CSCs), which sustain tumor growth. The CSC paradigm necessitates a reexamination of methodologies used to evaluate clinical efficacy of anticancer therapies, as well as strategies employed during preclinical drug development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.stem.2007.10.005 | DOI Listing |
Publication Analysis
Top Keywords
cancer stem
8
stem cells
8
evaluating therapeutic
4
therapeutic efficacy
4
efficacy cancer
4
cells challenges
4
challenges posed
4
posed paradigm
4
paradigm current
4
current measures
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!